JP7686571B2 - Ｔ細胞媒介性免疫を調節するための材料及び方法 - Google Patents

Ｔ細胞媒介性免疫を調節するための材料及び方法 Download PDF

Info

Publication number
JP7686571B2
JP7686571B2 JP2021565723A JP2021565723A JP7686571B2 JP 7686571 B2 JP7686571 B2 JP 7686571B2 JP 2021565723 A JP2021565723 A JP 2021565723A JP 2021565723 A JP2021565723 A JP 2021565723A JP 7686571 B2 JP7686571 B2 JP 7686571B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
trgv9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021565723A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020227457A5 (https=
JP2022533538A5 (https=
JP2022533538A (ja
Inventor
ガネサン，ラジクマール
グレワル，イクバル，エス．
シン，サンジャヤ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2022533538A publication Critical patent/JP2022533538A/ja
Publication of JPWO2020227457A5 publication Critical patent/JPWO2020227457A5/ja
Publication of JP2022533538A5 publication Critical patent/JP2022533538A5/ja
Priority to JP2024131038A priority Critical patent/JP2024170410A/ja
Application granted granted Critical
Publication of JP7686571B2 publication Critical patent/JP7686571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021565723A 2019-05-08 2020-05-07 Ｔ細胞媒介性免疫を調節するための材料及び方法 Active JP7686571B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024131038A JP2024170410A (ja) 2019-05-08 2024-08-07 Ｔ細胞媒介性免疫を調節するための材料及び方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962844959P 2019-05-08 2019-05-08
US201962844966P 2019-05-08 2019-05-08
US201962844976P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US62/844,959 2019-05-08
US62/844,966 2019-05-08
US62/844,976 2019-05-08
US62/844,995 2019-05-08
US62/844,970 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024131038A Division JP2024170410A (ja) 2019-05-08 2024-08-07 Ｔ細胞媒介性免疫を調節するための材料及び方法

Publications (4)

Publication Number Publication Date
JP2022533538A JP2022533538A (ja) 2022-07-25
JPWO2020227457A5 JPWO2020227457A5 (https=) 2023-05-16
JP2022533538A5 JP2022533538A5 (https=) 2023-05-16
JP7686571B2 true JP7686571B2 (ja) 2025-06-02

Family

ID=73051172

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565723A Active JP7686571B2 (ja) 2019-05-08 2020-05-07 Ｔ細胞媒介性免疫を調節するための材料及び方法
JP2024131038A Pending JP2024170410A (ja) 2019-05-08 2024-08-07 Ｔ細胞媒介性免疫を調節するための材料及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024131038A Pending JP2024170410A (ja) 2019-05-08 2024-08-07 Ｔ細胞媒介性免疫を調節するための材料及び方法

Country Status (22)

Country Link
US (2) US11667712B2 (https=)
EP (1) EP3965818A4 (https=)
JP (2) JP7686571B2 (https=)
KR (1) KR20220017892A (https=)
CN (1) CN113966231B (https=)
AU (1) AU2020267504A1 (https=)
BR (1) BR112021022089A2 (https=)
CA (1) CA3139508A1 (https=)
CL (1) CL2021002905A1 (https=)
CO (1) CO2021015998A2 (https=)
CR (1) CR20210548A (https=)
DO (1) DOP2021000229A (https=)
EC (1) ECSP21087921A (https=)
IL (1) IL287817A (https=)
JO (1) JOP20210297A1 (https=)
MA (1) MA55903A (https=)
MX (1) MX2021013532A (https=)
PE (1) PE20220763A1 (https=)
PH (1) PH12021552790A1 (https=)
SG (1) SG11202112021QA (https=)
TW (1) TW202108618A (https=)
WO (1) WO2020227457A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023515199A (ja) * 2020-02-27 2023-04-12 ヤンセン バイオテツク，インコーポレーテツド 免疫応答を調節するための材料及び方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531787B (zh) 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
CA3145523A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
US11639396B2 (en) * 2021-02-16 2023-05-02 Janssen Biotech, Inc. Antibody binding to a linker peptide
MX2023009950A (es) 2021-02-26 2023-11-10 Lava Therapeutics N V Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta.
IL326116A (en) * 2023-07-26 2026-03-01 Janssen Biotech Inc Materials and methods for cell culture
TW202537974A (zh) * 2023-11-15 2025-10-01 大陸商上海盛迪醫藥有限公司 Ｔｒｇｖ９結合蛋白及其醫藥用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用
JP2017535292A (ja) 2014-11-17 2017-11-30 アディセット バイオ， インコーポレイテッド 改変γδＴ細胞

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) * 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
BR112013002831A2 (pt) 2010-08-05 2016-11-01 Anaptysbio Inc anticorpos direcionados contra a il-17
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
JP2016539929A (ja) * 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EP3560955A4 (en) 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用
JP2017535292A (ja) 2014-11-17 2017-11-30 アディセット バイオ， インコーポレイテッド 改変γδＴ細胞

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
British Journal of Haematology，2010年，Vol.150，pp.574-586
Cancer Research，2014年，Vol.74，pp.1349-1360
Cellular Immunology，2015年，Vol.296，pp.41-49

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023515199A (ja) * 2020-02-27 2023-04-12 ヤンセン バイオテツク，インコーポレーテツド 免疫応答を調節するための材料及び方法

Also Published As

Publication number Publication date
US20210032338A1 (en) 2021-02-04
PE20220763A1 (es) 2022-05-16
CL2021002905A1 (es) 2022-06-17
ECSP21087921A (es) 2022-01-31
CN113966231A (zh) 2022-01-21
KR20220017892A (ko) 2022-02-14
SG11202112021QA (en) 2021-11-29
EP3965818A4 (en) 2023-05-31
US20240150464A1 (en) 2024-05-09
CA3139508A1 (en) 2020-11-12
EP3965818A1 (en) 2022-03-16
PH12021552790A1 (en) 2022-09-05
CR20210548A (es) 2022-02-11
AU2020267504A1 (en) 2021-12-02
JP2024170410A (ja) 2024-12-10
IL287817A (en) 2022-01-01
DOP2021000229A (es) 2022-07-31
CN113966231B (zh) 2025-04-01
WO2020227457A1 (en) 2020-11-12
TW202108618A (zh) 2021-03-01
BR112021022089A2 (pt) 2022-02-08
US11667712B2 (en) 2023-06-06
JOP20210297A1 (ar) 2023-01-30
MA55903A (fr) 2022-03-16
CO2021015998A2 (es) 2021-12-10
JP2022533538A (ja) 2022-07-25
MX2021013532A (es) 2022-02-11

Similar Documents

Publication Publication Date Title
JP7686571B2 (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
US20190382481A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
EP4228693A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
JP2022523442A (ja) 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
US12076413B2 (en) Compositions and methods for modulating delta gamma chain mediated immunity
US12448449B2 (en) Immune targeting molecules and uses thereof
US20260055185A1 (en) Materials and methods for modulating delta chain mediated immunity
US20250092134A1 (en) Compositions and methods for the modulation of beta chain-mediated immunity
CA3101270C (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
AU2024217296A1 (en) Anti-v beta 17/anti-cd123 bispecific antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250521

R150 Certificate of patent or registration of utility model

Ref document number: 7686571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150